Funding
Cancer
CANCER
The original LY.12 clinical trial was supported by grants nos. 015469 and 021039 from the Canadian Cancer Society Research Institute, and by Roche Canada and Eli Lilly Canada. Annette Hay has received research funding from Roche, AbbVie, Merck, Seattle Genetics, Janssen, Incyte, Amgen, Novartis.